Press Releases

Date Title and Summary Additional Formats
Toggle Summary Radius Health to Present at the 39th Annual J.P. Morgan Healthcare Conference
BOSTON , Jan. 06, 2021 (GLOBE NEWSWIRE) -- Radius Health , Inc. (Nasdaq: RDUS), today announced that Kelly Martin, President and CEO will present a virtual corporate update at the 39 th  Annual J.P. Morgan Healthcare Conference on Wednesday, January 13 at 9:10 a.m. EST .
View HTML
Toggle Summary Radius Health, Inc. Announces Acquisition of Orphan Disease Program
RAD011 is a pivotal-trial ready synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases Prader-Willi syndrome (“PWS”) will be the initial indication, which has been granted Orphan Drug and Fast Track Designation by the FDA Acquisition and
View HTML
Toggle Summary Radius Health Announces Commercial Agreement with Paladin Labs for Abaloparatide in Canada
Agreement incorporates TYMLOS ® and abaloparatide-TD Consideration includes upfront payment, milestones based on clinical, regulatory and commercial progression, as well as royalties Key first step in expanding the global footprint for the abaloparatide asset beyond the U.S.
View HTML
Toggle Summary Radius Health Announces Change to its Board of Directors
BOSTON , Jan. 04, 2021 (GLOBE NEWSWIRE) -- Radius Health , Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) announced today that Machelle Sanders and Dr. Andrew C. von Eschenbach have joined the Company’s board of directors. Ms. Sanders and Dr. von Eschenbach will fill vacancies created by the
View HTML
Toggle Summary Radius Health, Inc. Provides Business Update
Continued growth in net new patients for the month of November 2020 Company is on-track for record quarter in net revenue for TYMLOS-SC Research Agreement reached with MGH in October 2020 Hired Head of Clinical Development for the abaloparatide molecule WALTHAM, Mass. , Dec.
View HTML
Toggle Summary Radius Health, Inc.: Third Quarter 2020 Operating Results
TYMLOS ®   U.S. net sales of $50 million with 8% year-over-year growth; Total Revenues of $78 million Q3 commercial pivot to focus on high risk fracture segment is gaining traction: Net New U.S. Patients increased by 7+% in September 2020 vs. previous 3-month moving average and 10 +% in October vs.
View HTML
Toggle Summary Radius Health, Inc.: Progress Since May 2020
Completed e nrollment in 3 p ivotal c linical t rials; multiple data read outs in Q4 2021 Released meaningful abaloparatide histomorphometry data at recent ASBMR meeting Completed two business development transactions with existing oncology asset s Repositioned commercial effort to focus on high
View HTML
Toggle Summary Radius Health to Announce Third Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Thursday, November 5, 2020
WALTHAM, Mass. , Oct. 20, 2020 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter financial results on Thursday, November 5, 2020 . The Company will host a conference call and live audio webcast at 8:30 a.m.
View HTML
Toggle Summary Radius Health Divests RAD 140 Program to Ellipses Pharma
Business development step enables molecule to move forward Program progression will be at no financial risk to Radius Reinforces Radius ’   focus on execution of core business WALTHAM, Mass. , Oct. 01, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) announced today that the company has
View HTML
Toggle Summary Radius Health & Menarini Group Provide Elacestrant Update
Target enrollment milestone reached in the Phase 3 EMERALD study Life cycle planning advancing in parallel with current Phase 3 monotherapy program WALTHAM, Mass. and FLORENCE, Italy , Sept. 24, 2020 (GLOBE NEWSWIRE) -- Radius Health , Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) and the
View HTML